Rockwell Medical (NASDAQ: RMTI) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Rockwell Medical to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, risk, institutional ownership and valuation.

Risk & Volatility

Rockwell Medical has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Rockwell Medical’s competitors have a beta of 0.81, suggesting that their average stock price is 19% less volatile than the S&P 500.

Earnings & Valuation

This table compares Rockwell Medical and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Rockwell Medical $54.04 million -$21.07 million -15.79
Rockwell Medical Competitors $2.40 billion $905.93 million 3.57

Rockwell Medical’s competitors have higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Rockwell Medical and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rockwell Medical 1 0 1 1 2.67
Rockwell Medical Competitors 98 368 966 28 2.63

Rockwell Medical presently has a consensus price target of $9.33, suggesting a potential upside of 40.77%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 25.12%. Given Rockwell Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Rockwell Medical is more favorable than its competitors.

Institutional and Insider Ownership

21.4% of Rockwell Medical shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 15.9% of Rockwell Medical shares are held by company insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Rockwell Medical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rockwell Medical -39.68% -42.22% -27.15%
Rockwell Medical Competitors -538.85% -41.85% -24.81%

Rockwell Medical Company Profile

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.